Jade Biosciences
The Medical Director will lead and support Jade Biosciences’ clinical programs in nephrology, focusing on rare and immune-mediated kidney diseases. This physician-scientist role is based in a small biotech environment requiring scientific leadership, agility, and close cross-functional collaboration. The position reports to the Executive Medical Director of Clinical Development and is fully remote with periodic travel.
Jade Biosciences is a clinical-stage biotechnology company on a mission to transform the standard of care for patients with autoimmune diseases. The company develops a pipeline of potentially best-in-class therapies built on discovery-stage assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. Its lead candidate, JADE101, is designed to inhibit the cytokine APRIL and is being developed for the treatment of immunoglobulin A nephropathy (IgAN).
Zacks Research Downgrades Jade Biosciences (NASDAQ:JBIO) to Strong Sell
11 hours ago
Guggenheim raises Jade Biosciences stock price target on pipeline progress
1 day ago
Jade Biosciences Touts “Best-in-Class” Autoimmune Antibodies, JADE101 Phase 1 Readout Nears
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Jade Biosciences.
Jade Biosciences Announces $135 Million Private Placement
Oct 7, 2025
Associate Director/Medical Director, Clinical Development
Climb Bio
Medical Director, Global Medical Affairs, Nephrology
Travere Therapeutics
Executive Medical Director, Clinical Development, Hematology, Nephrology, & Transplant, Cell Therapy
AstraZeneca
Associate Principal Scientist, Immunology Biomarker Lead, Translational Medicine
Merck & Co., Inc.
Associate Principal Scientist, Immunology Biomarker Lead, Translational Medicine
Merck & Co., Inc.
Senior MSL – Rare Diseases (Haematology, Nephrology and Transplant)
AstraZeneca